LeonaBio (LONA) Income from Continuing Operations (2019 - 2026)
LeonaBio (LONA) reported Income from Continuing Operations of 17214000.0 for Q1 2026, down 80.52% year-over-year from 88349141.01 in Q1 2025, and up 78.09% on a QoQ basis from 78565000.0 in Q4 2025.
LeonaBio (LONA) has 8 years of Income from Continuing Operations data on file, last reported at 17214000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 80.52% year-over-year to 17214000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 109944000.0 (down 32.86% YoY) and the FY2025 annual result came in at 105610000.0, down 351933.33% from the prior year.
- Income from Continuing Operations advanced to 17214000.0 in Q1 2026 per LONA's latest filing, from 78565000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6874000.0 in Q3 2025 and bottomed at 78565000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 27687000.0 (2024), against an average of 26462588.24.
- Peak annual rise in Income from Continuing Operations reached 76.79% in 2025, while the deepest fall reached 404.72% in 2025.
- Tracing LONA's Income from Continuing Operations over 5 years: stood at 32927000.0 in 2022, then advanced by 11.88% to 29014000.0 in 2023, then jumped by 46.35% to 15566000.0 in 2024, then plunged by 404.72% to 78565000.0 in 2025, then jumped by 78.09% to 17214000.0 in 2026.
- Per Business Quant, the three latest LONA Income from Continuing Operations figures stand at 17214000.0 (Q1 2026), 78565000.0 (Q4 2025), and 6874000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - | -17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.21 Mn |
| Dec 31, 2025 | -78.57 Mn |
| Sep 30, 2025 | -6.87 Mn |
| Jun 30, 2025 | -7.29 Mn |
| Mar 31, 2025 | -9.54 Mn |
| Dec 31, 2024 | -15.57 Mn |
| Sep 30, 2024 | -29.62 Mn |
| Jun 30, 2024 | -28.03 Mn |
| Mar 31, 2024 | -27.69 Mn |
| Dec 31, 2023 | -29.01 Mn |
| Sep 30, 2023 | -35.04 Mn |
| Jun 30, 2023 | -31.64 Mn |
| Mar 31, 2023 | -29.77 Mn |
| Dec 31, 2022 | -32.93 Mn |
| Sep 30, 2022 | -24.13 Mn |
| Jun 30, 2022 | -23.57 Mn |
| Mar 31, 2022 | -23.39 Mn |
| Dec 31, 2021 | -18.78 Mn |
| Sep 30, 2021 | -17.83 Mn |
| Jun 30, 2021 | -16.64 Mn |
| Mar 31, 2021 | -10.78 Mn |
| Dec 31, 2020 | -9.08 Mn |
| Sep 30, 2020 | -7.40 Mn |
| Jun 30, 2020 | -2.25 Mn |
| Mar 31, 2020 | -1.27 Mn |
| Dec 31, 2019 | -1.12 Mn |
| Sep 30, 2019 | -1.54 Mn |